Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.33
THRX's Cash to Debt is ranked higher than
52% of the 1276 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. THRX: 0.33 )
THRX' s 10-Year Cash to Debt Range
Min: 0.33   Max: No Debt
Current: 0.33

Equity to Asset -0.43
THRX's Equity to Asset is ranked higher than
51% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. THRX: -0.43 )
THRX' s 10-Year Equity to Asset Range
Min: -2.39   Max: 0.67
Current: -0.43

-2.39
0.67
F-Score: 4
Z-Score: -2.94
M-Score: 20.70
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -911.18
THRX's Operating margin (%) is ranked higher than
59% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -85.54 vs. THRX: -911.18 )
THRX' s 10-Year Operating margin (%) Range
Min: -53258.33   Max: -9.58
Current: -911.18

-53258.33
-9.58
Net-margin (%) -1796.37
THRX's Net-margin (%) is ranked higher than
56% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. THRX: -1796.37 )
THRX' s 10-Year Net-margin (%) Range
Min: -50786.54   Max: -13.66
Current: -1796.37

-50786.54
-13.66
ROE (%) -444.65
THRX's ROE (%) is ranked higher than
50% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -32.57 vs. THRX: -444.65 )
THRX' s 10-Year ROE (%) Range
Min: -444.65   Max: -54.55
Current: -444.65

-444.65
-54.55
ROA (%) -28.39
THRX's ROA (%) is ranked higher than
73% of the 1282 Companies
in the Global Biotechnology industry.

( Industry Median: -26.11 vs. THRX: -28.39 )
THRX' s 10-Year ROA (%) Range
Min: -82.22   Max: -5.91
Current: -28.39

-82.22
-5.91
ROC (Joel Greenblatt) (%) -2098.48
THRX's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. THRX: -2098.48 )
THRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1267.07   Max: -133.15
Current: -2098.48

-1267.07
-133.15
Revenue Growth (3Y)(%) -35.60
THRX's Revenue Growth (3Y)(%) is ranked higher than
64% of the 721 Companies
in the Global Biotechnology industry.

( Industry Median: 0.40 vs. THRX: -35.60 )
THRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 125.7
Current: -35.6

0
125.7
EBITDA Growth (3Y)(%) -43.80
THRX's EBITDA Growth (3Y)(%) is ranked higher than
57% of the 758 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. THRX: -43.80 )
THRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -63.2   Max: -2.8
Current: -43.8

-63.2
-2.8
EPS Growth (3Y)(%) -22.40
THRX's EPS Growth (3Y)(%) is ranked higher than
66% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. THRX: -22.40 )
THRX' s 10-Year EPS Growth (3Y)(%) Range
Min: -47.1   Max: 12.9
Current: -22.4

-47.1
12.9
» THRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

THRX Guru Trades in Q2 2014

Richard Perry 1,517,208 sh (New)
Jean-Marie Eveillard 1,595,520 sh (unchged)
Jeremy Grantham Sold Out
Jim Simons Sold Out
Seth Klarman 20,395,056 sh (-1.50%)
Chuck Royce 4,300 sh (-81.22%)
» More
Q3 2014

THRX Guru Trades in Q3 2014

Richard Perry 1,831,099 sh (+20.69%)
Chuck Royce Sold Out
Jean-Marie Eveillard 1,593,620 sh (-0.12%)
Seth Klarman 19,815,983 sh (-2.84%)
» More
Q4 2014

THRX Guru Trades in Q4 2014

Richard Perry 4,026,736 sh (+119.91%)
Jean-Marie Eveillard 1,593,620 sh (unchged)
Seth Klarman 19,815,983 sh (unchged)
» More
2015

THRX Guru Trades in 2015

Seth Klarman 21,753,460 sh (+9.78%)
» More
» Details

Insider Trades

Latest Guru Trades with THRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 17.86
THRX's Forward P/E is ranked higher than
95% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. THRX: 17.86 )
N/A
P/S 218.00
THRX's P/S is ranked higher than
53% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 31.20 vs. THRX: 218.00 )
THRX' s 10-Year P/S Range
Min: 8.87   Max: 1520
Current: 218

8.87
1520
EV-to-EBIT -28.14
THRX's EV-to-EBIT is ranked higher than
84% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. THRX: -28.14 )
THRX' s 10-Year EV-to-EBIT Range
Min: -703.2   Max: -2.2
Current: -28.14

-703.2
-2.2
Current Ratio 18.33
THRX's Current Ratio is ranked higher than
95% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. THRX: 18.33 )
THRX' s 10-Year Current Ratio Range
Min: 2.41   Max: 18.33
Current: 18.33

2.41
18.33
Quick Ratio 18.33
THRX's Quick Ratio is ranked higher than
95% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. THRX: 18.33 )
THRX' s 10-Year Quick Ratio Range
Min: 2.41   Max: 18.33
Current: 18.33

2.41
18.33
Days Inventory 9.00
THRX's Days Inventory is ranked higher than
98% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. THRX: 9.00 )
THRX' s 10-Year Days Inventory Range
Min: 0   Max: 0
Current: 9

Days Sales Outstanding 410.62
THRX's Days Sales Outstanding is ranked higher than
67% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 111.38 vs. THRX: 410.62 )
THRX' s 10-Year Days Sales Outstanding Range
Min: 2.86   Max: 3530.67
Current: 410.62

2.86
3530.67

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.60
THRX's Dividend Yield is ranked higher than
94% of the 202 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. THRX: 4.60 )
THRX' s 10-Year Dividend Yield Range
Min: 1.19   Max: 4.44
Current: 4.6

1.19
4.44
Yield on cost (5-Year) 4.60
THRX's Yield on cost (5-Year) is ranked higher than
89% of the 206 Companies
in the Global Biotechnology industry.

( Industry Median: 1.28 vs. THRX: 4.60 )
THRX' s 10-Year Yield on cost (5-Year) Range
Min: 1.19   Max: 4.44
Current: 4.6

1.19
4.44
Share Buyback Rate -10.90
THRX's Share Buyback Rate is ranked higher than
76% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -9.90 vs. THRX: -10.90 )
THRX' s 10-Year Share Buyback Rate Range
Min: -2.2   Max: -105.4
Current: -10.9

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 3.40
THRX's Price/Median PS Value is ranked higher than
68% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. THRX: 3.40 )
THRX' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 15.87
Current: 3.4

0.2
15.87
Earnings Yield (Greenblatt) -3.60
THRX's Earnings Yield (Greenblatt) is ranked higher than
76% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. THRX: -3.60 )
THRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -9.6   Max: 0
Current: -3.6

-9.6
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HVE.Germany,
Theravance Inc., was incorporated in Delaware in November 1996 under the name Advanced Medicine, Inc. and began operations in May 1997. The Company changed its name to Theravance, Inc. in April 2002.is a biopharmaceutical company with a pipeline of internally discovered product candidates and collaborations with pharmaceutical companies. The Company is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. Its key programs include: RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, "FF/VI"), ANORO ELLIPTA (umeclidinium bromide/vilanterol, "UMEC/VI") and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with Glaxo Group Limited (GSK), and its Long-Acting Muscarinic Antagonist program. Its drug discovery efforts are based on the principles of multivalency. Multivalency refers to the simultaneous attachment of a single molecule to multiple binding sites on one or more biological targets. When compared to monovalency, whereby a molecule attaches to only one binding site, multivalency can significantly increase a compound's potency, duration of action and/or selectivity. Multivalent compounds generally consist of several individual small molecules, at least one of which is biologically active when bound to its target, joined by linking components. The Company has limited in-house active pharmaceutical ingredient (API) production capabilities, and rely primarily on a number of third parties, including contract manufacturing organizations and collaborative partners, to produce active pharmaceutical ingredient and drug product. The development and commercialization of VIBATIV and its product candidates and ongoing research are subject to extensive regulation by governmental authorities in the United States and other countries.
» More Articles for THRX

Headlines

Articles On GuruFocus.com
Richard Perry's Fourth-Quarter Transactions Had High Impact on Portfolio Feb 16 2015 
Seth Klarman Keeps Buying LNG, KERX, PBF And Keeps Selling THRX Dec 05 2014 
Data Published on Anoro(R) Ellipta(R) Demonstrate Improved Lung Function Compared to Tiotropium Oct 17 2014 
Theravance, Inc. Appoints Eric d'Esparbes as Senior Vice President and Chief Financial Officer Oct 15 2014 
Seth Klarman Buys Cheniere Energy, Keryx Biopharmaceuticals, Idenix Pharmaceuticals, Sells BP, Fidel May 15 2014 
Seth Klarman Buys Micron Technology, Theravance, PBF Energy, Sells BP, AIG, Yamana Gold Nov 13 2013 
Seth Klarman's Top 5 Second Quarter Holdings Aug 14 2013 
Top Four from Baupost’s Seth Klarman Jul 18 2013 
What Can We Earn If We Invest in the Top Five Holdings of the Baupost Group? May 29 2013 
Weekly CEO Sells Highlight: Texas Roadhouse Inc., Theravance Inc., AmerisourceBergen Corp. and Nuanc May 06 2013 

More From Other Websites
Nasdaq stocks posting largest percentage decreases Mar 30 2015
Should Theravance (THRX) Be On Your Radar Now? - Tale of the Tape Mar 24 2015
KB Home and Biogen are big market movers Mar 20 2015
Theravance/Glaxo's Breo Ellipta Gets Mixed FDA Panel View - Analyst Blog Mar 20 2015
THERAVANCE INC Files SEC form 8-K, Other Events Mar 20 2015
FDA panel backs Glaxo inhaler for adults, not adolescents Mar 19 2015
GSK and Theravance announce outcome of US FDA Advisory Committee on BREO® ELLIPTA® in asthma Mar 19 2015
GSK and Theravance Announce Outcome of US FDA Advisory Committee on BREO(R) ELLIPTA(R) in Asthma Mar 19 2015
FDA panel backs Glaxo asthma drug for adults, not adolescents Mar 19 2015
Theravance Announces Trading in Common Stock Halted Mar 19 2015
Pharmacyclics' Imbruvica Encourages in a Phase III Study - Analyst Blog Mar 17 2015
THERAVANCE INC Files SEC form 8-K, Regulation FD Disclosure Mar 17 2015
FDA staff finds no new safety problems with Glaxo's asthma drug Mar 17 2015
Billionaire Seth Klarman’s Biotech Stock Picks Mar 15 2015
Theravance Biopharma Announces Initiation of Phase 2b Study of Velusetrag (TD-5108) for the... Mar 12 2015
Theravance Biopharma Q4 Loss Widens Y/Y, Revenues Up - Analyst Blog Mar 11 2015
Heat Biologics' Bladder Cancer Drug Gets Fast Track Status - Analyst Blog Mar 10 2015
Theravance Bio reports 4Q loss Mar 10 2015
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results Mar 10 2015
Theravance Biopharma Announces New Employment Inducement Awards Mar 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK